HomePress-release

Redding, California - January 19, 2026

Transcriptome Sequencing Market to be Worth $11.83 Billion by 2035

Transcriptome Sequencing Market by Product & Service (Consumables, Instruments, Software & Services), Technology (Bulk RNA-seq, Single-cell RNA-seq, Spatial Transcriptomics, Long-read RNA Sequencing), Application, and End User - Global Forecast to 2035

Meticulous Research®---a leading market research company, published a research report titled, "Transcriptome Sequencing Market by Product & Service (Consumables, Instruments, Software & Services), Technology (Bulk RNA-seq, Single-cell RNA-seq, Spatial Transcriptomics, Long-read RNA Sequencing), Application (Drug Discovery, Clinical Diagnostics, Personalized Medicine), End User - Global Forecast to 2035".

According to the latest report from Meticulous Research®, the transcriptome sequencing market is expected to reach $11.83 billion by 2035, growing at a rate of 7.3% from 2025 to 2035. This market growth is fueled by decreasing sequencing costs, higher throughput capacity, increased use of precision medicine and companion diagnostics, a growing demand for single-cell and spatial transcriptomics applications, and rising investments in drug discovery and biomarker development. However, high capital investments for sequencing infrastructure, the complexity of bioinformatics data analysis, and a shortage of skilled bioinformatics professionals are limiting market growth.

Additionally, advancements in long-read sequencing technologies for full-length transcript analysis, the integration of AI and machine learning in transcriptome data analysis, and increased use in clinical diagnostics and liquid biopsy are expected to create growth opportunities for market players. On the other hand, standardization issues across sequencing platforms and workflows present challenges to market growth.

The report profiles key players in the transcriptome sequencing market, including Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Oxford Nanopore Technologies plc (U.K.), 10x Genomics, Inc. (U.S.), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Bio-Rad Laboratories, Inc. (U.S.), Takara Bio Inc. (Japan), Becton, Dickinson and Company (U.S.), Standard BioTools Inc. (U.S.), Element Biosciences, Inc. (U.S.), MGI Tech Co., Ltd. (China), and Singular Genomics Systems, Inc. (U.S.).

The transcriptome sequencing market is divided by Product & Service, Technology, Application, End User, and Geography. The report also assesses competitors in the industry and analyzes the transcriptome sequencing market by region and country.

Among the product and service types examined, the consumables segment led the transcriptome sequencing market in 2025. This dominance is due to the repeated purchasing of reagents and kits for ongoing sequencing, continuous use of high-quality reagents in transcriptome studies, the expanding application of sequencing in pharmaceutical, biotechnology, and academic research sectors, and new advanced consumables offered by key players to meet researchers' needs. For example, in May 2024, QIAGEN released its QIAseq Multimodal DNA/RNA Library Kit, which allows researchers to prepare both DNA and RNA libraries from one sample. The consumables segment is also predicted to have the highest growth rate at 8.1% during the forecast period.

Among the technologies discussed, the bulk RNA-seq segment dominated the transcriptome sequencing market in 2025. Bulk RNA-seq is the most developed and cost-effective transcriptomic technology available today. Its wide adoption in academic research, pharmaceutical R&D, and clinical studies is due to reliable workflows and reproducibility. It can handle high-throughput gene expression profiling across large sample groups, making it ideal for population studies and biomarker discovery. Established library preparation kits and bioinformatics workflows significantly lower technical hurdles, and its lower cost per sample compared to advanced transcriptomic methods makes it the go-to choice in budget-limited research settings. Meanwhile, the spatial transcriptomics segment is anticipated to have the highest growth rate of 16.5% during the forecast period. This technology addresses the main limitation of traditional RNA-seq methods by maintaining spatial context. It allows researchers to measure gene expression while keeping track of cell locations within tissues, providing vital insights into tissue diversity and tumor environments. Its increasing significance in oncology, immunology, and neuroscience—where spatial cell interactions impact disease progression—along with its rapid adoption in precision medicine research and advanced pathology workflows, are key drivers of its remarkable growth.

Among the applications covered, the drug discovery and development segment dominated the transcriptome sequencing market in 2025. Pharmaceutical and biotechnology companies extensively use RNA sequencing for identifying and validating targets, discovering biomarkers, and conducting toxicogenomics studies. This technology enables more precise gene expression profiling, which supports the development of targeted therapies, especially in oncology, neurology, and immunology. The ongoing and large-scale usage is driven by high research budgets and multiple ongoing projects, translating into a consistent demand for sequencing platforms and consumables. However, the basic and translational research segment is projected to achieve the highest growth rate of 8.9% during the forecast period. The rapid growth of academic, government-funded, and collaborative research projects focused on understanding disease biology at the molecular level is noteworthy. The increasing use in functional genomics, cell differentiation studies, developmental biology, immunology, and neuroscience, along with the rise of single-cell RNA sequencing, spatial transcriptomics, and long-read RNA sequencing, are broadening the scope of basic research. Strong acceptance among academic institutions and research groups, especially in emerging research hubs, is also contributing to this segment's growth.

Among end users, the pharmaceutical and biotechnology companies segment dominated the transcriptome sequencing market in 2025. Transcriptomic data has become a key asset throughout the drug development process, with widespread RNA sequencing usage for target discovery, biomarker identification, patient stratification, mechanism-of-action studies, toxicity profiling, and response monitoring. Continuous usage is supported by significant research budgets and long development timelines. The growing integration of transcriptomics with genomics, proteomics, and AI-driven analytics has also bolstered this segment's position. However, the contract research organizations (CROs) and sequencing service providers segment is expected to show the highest growth rate of 8.9% over the forecast period. This growth is fueled by an industry shift towards outsourcing and flexible R&D models. Many companies prefer to outsource transcriptome sequencing to cut costs and access expertise. CROs are increasingly providing comprehensive solutions that extend from sample preparation to bioinformatics analysis, and this trend is particularly strong for single-cell RNA-seq, spatial transcriptomics, and large-scale multi-omics studies that require advanced infrastructure.

By geography, North America dominated the transcriptome sequencing market in 2025 with a share of about 40%. The region's large market share results from early adoption of advanced genomic technologies, a strong life sciences environment, and a high concentration of pharmaceutical and biotechnology companies. There has been consistent investment in biomedical research and robust public and private funding supporting extensive use of RNA sequencing in drug discovery and clinical studies. The well-established research infrastructure and availability of skilled bioinformatics professionals also play critical roles, along with mature regulatory and data management frameworks that enable quick integration of new transcriptomic technologies in the area.

Meanwhile, Asia-Pacific is expected to post the highest growth rate of around 8.5% during the forecast period. Rapid advancement in genomics infrastructure, research capacity, and healthcare investments in countries such as China, India, Japan, South Korea, and Australia are pivotal. Increased government funding for national genomics initiatives and precision medicine programs, a large and genetically diverse population suitable for extensive studies and biomarker discovery, growing numbers of local sequencing service providers, CROs, and biotech startups, along with comparatively lower operational and labor costs are key factors driving market growth in Asia-Pacific.

Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=6358

Key questions answered in the report-

Which are the high-growth market segments in terms of product & service, technology, application, end user, and geography?
What was the historical market for transcriptome sequencing across the globe?
What are the market forecasts and estimates for the period 2025–2035?
What are the major drivers, restraints, opportunities, and challenges in the transcriptome sequencing market?
Who are the major players operating in the transcriptome sequencing market?
What is the competitive landscape like, and who are the leaders in the transcriptome sequencing market?
What are the recent developments in the transcriptome sequencing market?
What are the different strategies adopted by the major players in the transcriptome sequencing market?
What are the geographical trends and high-growth regions/countries?

Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research

3D Printing

5G Technology

Advanced Chemical & Materials

Agrochemicals

Algae Products

Alternative Proteins

Animal Health

Artificial Intelligence

Automotive Technologies

Big Data Analytics

Climate Technologies

Edible Insects

Electric Vehicle

Food & Agriculture Technologies

Hydrogen Technologies

Internet Of Things

In Vitro Diagnostics

Laboratory Instrumentation

Language Learning Technologies

Medical Technologies

Next Generation Technologies

Processing & Packaging Technologies

Robotics & Automation

Smart Technologies

Water & WastewaterTechnologies

Miscellaneous / Others

Redding, California - January 19, 2026

Transcriptome Sequencing Market to be Worth $11.83 Billion by 2035

Transcriptome Sequencing Market by Product & Service (Consumables, Instruments, Software & Services), Technology (Bulk RNA-seq, Single-cell RNA-seq, Spatial Transcriptomics, Long-read RNA Sequencing), Application, and End User - Global Forecast to 2035

Recommended Readings

Advanced Chemical &
Materials

Food & Agriculture
Technologies

Next Generation
Technologies

Processing & Packaging
Technologies

Water & Wastewater
Technologies